Advances in targeting cell surface signalling molecules for immune modulation

Nature Reviews Drug Discovery

Volumn 12, Issue 2, 2013, Pages 130-146

  Yao, Sheng ^a,b   Zhu, Yuwen ^a   Chen, Lieping ^a  

^a YALE CANCER CENTER   (United States)

^b Amplimmune Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; APRIL PROTEIN; B CELL ACTIVATING FACTOR; B CELL ACTIVATING FACTOR RECEPTOR; B CELL MATURATION ANTIGEN; BELATACEPT; BELIMUMAB; CD28 ANTIGEN; CD40 ANTIGEN; CD40 LIGAND; CONATUMUMAB; CYCLOSPORIN A; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GALIXIMAB; IMMUNOGLOBULIN; IMMUNOGLOBULIN RECEPTOR; INDUCIBLE T CELL COSTIMULATOR LIGAND; IPILIMUMAB; LEXATUMUMAB; MAPATUMUMAB; NIVOLUMAB; PIDILIZUMAB; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 LIGAND 2; PROGRAMMED DEATH 1 RECEPTOR; RITUXIMAB; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR; UNINDEXED DRUG; V SET DOMAIN CONTAINING T CELL ACTIVATION INHIBITOR 1;

ABSENCE OF SIDE EFFECTS; ADVANCED CANCER; CANCER COMBINATION CHEMOTHERAPY; COLITIS; COLORECTAL CANCER; DERMATITIS; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; FOLLICULAR LYMPHOMA; HEMATOLOGIC MALIGNANCY; HEPATITIS; HODGKIN DISEASE; HUMAN; HYPOTHYROIDISM; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; IMMUNOTOXICITY; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY CARCINOMA; KIDNEY GRAFT REJECTION; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; MELANOMA; METASTATIC MELANOMA; NONHODGKIN LYMPHOMA; NONHUMAN; POLYARTHRITIS; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SOLID TUMOR; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE ACTIVATION; TREATMENT OUTCOME;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, SURFACE; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOMODULATION; MOLECULAR TARGETED THERAPY; RECOMBINANT FUSION PROTEINS;

EID: 84873372202     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd3877     Document Type: Review

References (173)

1. Chan, A. C. & Carter, P. J. Therapeutic antibodies for autoimmunity and inflammation. Nature Rev. Immunol. 10, 301-316 (2010).
2. Weiner, L. M., Surana, R. & Wang, S. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nature Rev. Immunol. 10, 317-327 (2010).
3. Zhu, Y., Yao, S. & Chen, L. Cell surface signaling molecules in the control of immune responses: a tide model. Immunity 34, 466-478 (2011).
4. Carreno, B. M. & Collins, M. The B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune responses. Annu. Rev. Immunol. 20, 29-53 (2002).
5. Chen, L. Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nature Rev. Immunol. 4, 336-347 (2004).
6. Topalian, S. L. et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366, 2443-2454 (2012).
7. Linsley, P. S., Clark, E. A. & Ledbetter, J. A. T-cell antigen CD28 mediates adhesion with B cells by interacting with activation antigen B7/BB-1. Proc. Natl Acad. Sci. USA 87, 5031-5035 (1990).
8. Linsley, P. S. et al. CTLA-4 is a second receptor for the B cell activation antigen B7. J. Exp. Med. 174, 561-569 (1991).
9. Watanabe, N. et al. BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1. Nature Immunol. 4, 670-679 (2003).
10. kip1 and cell cycle progression by activation of the PI3K/PKB signaling pathway in primary human T cells. J. Immunol. 168, 2729-2736 (2002).
11. Boise, L. H. et al. CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-XL. Immunity 3, 87-98 (1995).
12. Parry, R. V., Rumbley, C. A., Vandenberghe, L. H., June, C. H. & Riley, J. L. CD28 and inducible costimulatory protein Src homology 2 binding domains show distinct regulation of phosphatidylinositol 3-kinase, Bcl-xL, and IL-2 expression in primary human CD4 T lymphocytes. J. Immunol. 171, 166-174 (2003).
13. Krummel, M. F. & Allison, J. P. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J. Exp. Med. 182, 459-465 (1995).
14. Walunas, T. L. et al. CTLA-4 can function as a negative regulator of T cell activation. Immunity 1, 405-413 (1994).
15. Tivol, E. A. et al. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 3, 541-547 (1995).
16. Waterhouse, P. et al. Lymphoproliferative disorders with early lethality in mice deficient in CTLA-4. Science 270, 985-988 (1995).
17. Hutloff, A. et al. ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28. Nature 397, 263-266 (1999).
18. Yoshinaga, S. K. et al. T-cell co-stimulation through B7RP-1 and ICOS. Nature 402, 827-832 (1999).
19. Dong, C. et al. ICOS co-stimulatory receptor is essential for T-cell activation and function. Nature 409, 97-101 (2001).
20. McAdam, A. J. et al. ICOS is critical for CD40-mediated antibody class switching. Nature 409, 102-105 (2001).
21. Yao, S. et al. B7-H2 is a costimulatory ligand for CD28 in human. Immunity 34, 729-740 (2011).
22. Shiao, S. L., McNiff, J. M. & Pober, J. S. Memory T cells and their costimulators in human allograft injury. J. Immunol. 175, 4886-4896 (2005).
23. Zuberek, K. et al. Comparable in vivo efficacy of CD28/B7, ICOS/GL50, and ICOS/GL50B costimulatory pathways in murine tumor models: IFNγ-dependent enhancement of CTL priming, effector functions, and tumor specific memory CTL. Cell. Immunol. 225, 53-63 (2003).
24. Chen, L. et al. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 71, 1093-1102 (1992).
25. Huang, A. Y., Bruce, A. T., Pardoll, D. M. & Levitsky, H. I. Does B7-1 expression confer antigen-presenting cell capacity to tumors in vivo? J. Exp. Med. 183, 769-776 (1996).
26. Sturmhoefel, K. et al. Potent activity of soluble B7-IgG fusion proteins in therapy of established tumors and as vaccine adjuvant. Cancer Res. 59, 4964-4972 (1999).
27. Runyon, K. et al. The combination of chemotherapy and systemic immunotherapy with soluble B7-immunoglobulin G leads to cure of murine leukemia and lymphoma and demonstration of tumor-specific memory responses. Blood 97, 2420-2426 (2001).
28. Liu, A., Hu, P., Khawli, L. A. & Epstein, A. L. Combination B7-Fc fusion protein treatment and Treg cell depletion therapy. Clin. Cancer Res. 11, 8492-8502 (2005).
29. + T cell responses by ICOS/B7H costimulation. J. Immunol. 167, 132-139 (2001).
30. + T lymphocytes in vivo. J. Exp. Med. 194, 1339-1348 (2001).
31. Kwon, E. D. et al. Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy. Proc. Natl Acad. Sci. USA 96, 15074-15079 (1999).
32. van Elsas, A., Hurwitz, A. A. & Allison, J. P. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J. Exp. Med. 190, 355-366 (1999).
33. Leach, D. R., Krummel, M. F. & Allison, J. P. Enhancement of antitumor immunity by CTLA-4 blockade. Science 271, 1734-1736 (1996).
34. Hernandez, J., Ko, A. & Sherman, L. A. CTLA-4 blockade enhances the CTL responses to the p53 self-tumor antigen. J. Immunol. 166, 3908-3914 (2001).
35. + regulatory cells that control intestinal inflammation. J. Exp. Med. 192, 295-302 (2000).
36. + regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J. Exp. Med. 192, 303-310 (2000).
37. Peggs, K. S., Quezada, S. A., Chambers, C. A., Korman, A. J. & Allison, J. P. Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J. Exp. Med. 206, 1717-1725 (2009).
38. Kaehler, K. C. et al. Update on immunologic therapy with anti-CTLA-4 antibodies in melanoma: identification of clinical and biological response patterns, immune-related adverse events, and their management. Semin. Oncol. 37, 485-498 (2010).
39. Hodi, F. S. et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc. Natl Acad. Sci. USA 100, 4712-4717 (2003).
40. Phan, G. Q. et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc. Natl Acad. Sci. USA 100, 8372-8377 (2003).
41. Thompson, C. B. et al. CD28 activation pathway regulates the production of multiple T-cell-derived lymphokines/cytokines. Proc. Natl Acad. Sci. USA 86, 1333-1337 (1989).
42. Suntharalingam, G. et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N. Engl. J. Med. 355, 1018-1028 (2006).
43. Grohmann, U. et al. CTLA-4-Ig regulates tryptophan catabolism in vivo. Nature Immunol. 3, 1097-1101 (2002).
44. Sharpe, A. H. & Freeman, G. J. The B7-CD28 superfamily. Nature Rev. Immunol. 2, 116-126 (2002).
45. Bluestone, J. A., St Clair, E. W. & Turka, L. A. CTLA4Ig: bridging the basic immunology with clinical application. Immunity 24, 233-238 (2006).
46. Thompson, R. H. et al. Costimulatory B7-H1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target. Proc. Natl Acad. Sci. USA 101, 17174-17179 (2004).
47. Larsen, C. P. et al. Belatacept-based regimens versus a cyclosporine A-based regimen in kidney transplant recipients: 2-year results from the BENEFIT and BENEFIT-EXT studies. Transplantation 90, 1528-1535 (2010).
48. Vinjamaram, S., Czuczman, M. S. & Hernandez-Ilizaliturri, F. J. The use of galiximab in non-Hodgkin lymphoma. Clin. Lymphoma Myeloma 8, 277-282 (2008).
49. Czuczman, M. S. et al. Phase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphoma. J. Clin. Oncol. 23, 4390-4398 (2005).
50. Tafuri, A. et al. ICOS is essential for effective T-helper-cell responses. Nature 409, 105-109 (2001).
51. Grimbacher, B. et al. Homozygous loss of ICOS is associated with adult-onset common variable immunodeficiency. Nature Immunol. 4, 261-268 (2003).
52. Hu, Y. L., Metz, D. P., Chung, J., Siu, G. & Zhang, M. B7RP-1 blockade ameliorates autoimmunity through regulation of follicular helper T cells. J. Immunol. 182, 1421-1428 (2009).
53. Dong, H., Zhu, G., Tamada, K. & Chen, L. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nature Med. 5, 1365-1369 (1999).
54. Tseng, S. Y. et al. B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells. J. Exp. Med. 193, 839-846 (2001).
55. Mazanet, M. M. & Hughes, C. C. B7-H1 is expressed by human endothelial cells and suppresses T cell cytokine synthesis. J. Immunol. 169, 3581-3588 (2002).
56. Wiendl, H. et al. Human muscle cells express a B7-related molecule, B7-H1, with strong negative immune regulatory potential: a novel mechanism of counterbalancing the immune attack in idiopathic inflammatory myopathies. FASEB J. 17, 1892-1894 (2003).
57. Yamazaki, T. et al. Expression of programmed death 1 ligands by murine T cells and APC. J. Immunol. 169, 5538-5545 (2002).
58. Ishida, Y., Agata, Y., Shibahara, K. & Honjo, T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 11, 3887-3895 (1992).
59. Agata, Y. et al. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int. Immunol. 8, 765-772 (1996).
60. Yao, S. et al. PD-1 on dendritic cells impedes innate immunity against bacterial infection. Blood 113, 5811-5818 (2009).
61. + T cell activation during HIV infection. Nature Med. 16, 452-459 (2010).
62. Freeman, G. J. et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J. Exp. Med. 192, 1027-1034 (2000).
63. Latchman, Y. et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nature Immunol. 2, 261-268 (2001).
64. Nishimura, H. et al. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science 291, 319-322 (2001).
65. Okazaki, T. et al. Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice. Nature Med. 9, 1477-1483 (2003).
66. Nishimura, H., Nose, M., Hiai, H., Minato, N. & Honjo, T. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 11, 141-151 (1999).
67. -/- mice as an efficient animal model of type I diabetes. Proc. Natl Acad. Sci. USA 102, 11823-11828 (2005).
68. Tsushima, F. et al. Interaction between B7-H1 and PD-1 determines initiation and reversal of T-cell anergy. Blood 110, 180-185 (2007).
69. Ansari, M. J. et al. The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice. J. Exp. Med. 198, 63-69 (2003).
70. Yao, S. & Chen, L. Reviving exhausted T lymphocytes during chronic virus infection by B7-H1 blockade. Trends Mol. Med. 12, 244-246 (2006).
71. Zou, W. & Chen, L. Inhibitory B7-family molecules in the tumour microenvironment. Nature Rev. Immunol. 8, 467-477 (2008).
72. Dong, H. et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nature Med. 8, 793-800 (2002).
73. Thompson, R. H. et al. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res. 66, 3381-3385 (2006).
74. Zajac, A. J. et al. Viral immune evasion due to persistence of activated T cells without effector function. J. Exp. Med. 188, 2205-2213 (1998).
75. Hirano, F. et al. Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res. 65, 1089-1096 (2005).
76. Azuma, T. et al. B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells. Blood 111, 3635-3643 (2008).
77. Strome, S. E. et al. B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma. Cancer Res. 63, 6501-6505 (2003).
78. Iwai, Y. et al. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc. Natl Acad. Sci. USA 99, 12293-12297 (2002).
79. Butte, M. J., Keir, M. E., Phamduy, T. B., Sharpe, A. H. & Freeman, G. J. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity 27, 111-122 (2007).
80. Park, J. J. et al. B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance. Blood 116, 1291-1298 (2010).
81. Yi, T. et al. Host APCs augment in vivo expansion of donor natural regulatory T cells via B7H1/B7.1 in allogeneic recipients. J. Immunol. 186, 2739-2749 (2011).
82. Brahmer, J. R. et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J. Clin. Oncol. 28, 3167-3175 (2010).
83. Berger, R. et al. Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin. Cancer Res. 14, 3044-3051 (2008).
84. Taube, J. M. et al. Colocalization of inflammatory response with B7-H1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci. Transl. Med. 4, 127ra37 (2012).
85. Brahmer, J. R. et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366, 2455-2465 (2012).
86. Mkrtichyan, M. et al. Anti-PD-1 synergizes with cyclophosphamide to induce potent anti-tumor vaccine effects through novel mechanisms. Eur. J. Immunol. 41, 2977-2986 (2011).
87. Sedy, J. R. et al. B and T lymphocyte attenuator regulates T cell activation through interaction with herpesvirus entry mediator. Nature Immunol. 6, 90-98 (2005).
88. + T cells that can be partially reversed by vaccination. J. Clin. Invest. 120, 157-167 (2010).
89. Sakoda, Y. et al. Dichotomous regulation of GVHD through bidirectional functions of the BTLA-HVEM pathway. Blood 11 7, 2506-2514 (2011).
90. Albring, J. C. et al. Targeting of B and T lymphocyte associated (BTLA) prevents graft-versus-host disease without global immunosuppression. J. Exp. Med. 207, 2551-2559 (2010).
91. Prasad, D. V., Richards, S., Mai, X. M. & Dong, C. B7S1, a novel B7 family member that negatively regulates T cell activation. Immunity 18, 863-873 (2003).
92. Sica, G. L. et al. B7-H4, a molecule of the B7 family, negatively regulates T cell immunity. Immunity 18, 849-861 (2003).
93. Zang, X. et al. B7x: a widely expressed B7 family member that inhibits T cell activation. Proc. Natl Acad. Sci. USA 100, 10388-10392 (2003).
94. Kryczek, I. et al. B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J. Exp. Med. 203, 871-881 (2006).
95. Kryczek, I. et al. Relationship between B7-H4, regulatory T cells, and patient outcome in human ovarian carcinoma. Cancer Res. 67, 8900-8905 (2007).
96. Choi, I. H. et al. Genomic organization and expression analysis of B7-H4, an immune inhibitory molecule of the B7 family. J. Immunol. 171, 4650-4654 (2003).
97. Arigami, T. et al. Expression of B7-H4 in blood of patients with gastric cancer predicts tumor progression and prognosis. J. Surg. Oncol. 102, 748-752 (2010).
98. Jiang, J. et al. Tumor expression of B7-H4 predicts poor survival of patients suffering from gastric cancer. Cancer Immunol. Immunother. 59, 1707-1714 (2010).
99. Quandt, D., Fiedler, E., Boettcher, D., Marsch, W. & Seliger, B. B7-H4 expression in human melanoma: its association with patients' survival and antitumor immune response. Clin. Cancer Res. 17, 3100-3111 (2011).
100. Azuma, T. et al. Potential role of decoy B7-H4 in the pathogenesis of rheumatoid arthritis: a mouse model informed by clinical data. PLoS Med. 6, e1000166 (2009).
101. Wang, X. et al. Early treatment of NOD mice with B7-H4 reduces the incidence of autoimmune diabetes. Diabetes 60, 3246-3255 (2011).
102. Triebel, F. et al. LAG-3, a novel lymphocyte activation gene closely related to CD4. J. Exp. Med. 171, 1393-1405 (1990).
103. Sierro, S., Romero, P. & Speiser, D. E. The CD4-like molecule LAG-3, biology and therapeutic applications. Expert Opin. Ther. Targets 15, 91-101 (2011).
104. Hannier, S., Tournier, M., Bismuth, G. & Triebel, F. CD3/TCR complex-associated lymphocyte activation gene-3 molecules inhibit CD3/TCR signaling. J. Immunol. 161, 4058-4065 (1998).
105. + T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nature Immunol. 10, 29-37 (2009).
106. Woo, S. R. et al. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T cell function to promote tumoral immune escape. Cancer Res. 72, 917-927 (2011).
107. + T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. Proc. Natl Acad. Sci. USA 107, 7875-7880 (2010).
108. + T cell accumulation and effector function in murine self-and tumor-tolerance systems. J. Clin. Invest. 117, 3383-3392 (2007).
109. Fougeray, S., Brignone, C. & Triebel, F. A soluble LAG-3 protein as an immunopotentiator for therapeutic vaccines: preclinical evaluation of IMP321. Vaccine 24, 5426-5433 (2006).
110. Brignone, C., Grygar, C., Marcu, M., Perrin, G. & Triebel, F. IMP321 (sLAG-3) safety and T cell response potentiation using an influenza vaccine as a model antigen: a single-blind phase I study. Vaccine 25, 4641-4650 (2007).
111. Brignone, C., Grygar, C., Marcu, M., Perrin, G. & Triebel, F. IMP321 (sLAG-3), an immunopotentiator for T cell responses against a HBsAg antigen in healthy adults: a single blind randomised controlled phase I study. J. Immune Based Ther. Vaccines 5, 5 (2007).
112. Brignone, C., Escudier, B., Grygar, C., Marcu, M. & Triebel, F. A phase I pharmacokinetic and biological correlative study of IMP321, a novel MHC class II agonist, in patients with advanced renal cell carcinoma. Clin. Cancer Res. 15, 6225-6231 (2009).
113. Wang, L. et al. VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses. J. Exp. Med. 208, 577-592 (2011).
114. Flies, D. B., Wang, S., Xu, H. & Chen, L. Cutting edge: a monoclonal antibody specific for the programmed death-1 homolog prevents graft-versus-host disease in mouse models. J. Immunol. 187, 1537-1541 (2011).
115. Watts, T. H. TNF/TNFR family members in costimulation of T cell responses. Annu. Rev. Immunol. 23, 23-68 (2005).
116. Grewal, I. S. Overview of TNF superfamily: a chest full of potential therapeutic targets. Adv. Exp. Med. Biol. 647, 1-7 (2009).
117. Abdulghani, J. & El-Deiry, W. S. TRAIL receptor signaling and therapeutics. Expert Opin. Ther. Targets 14, 1091-1108 (2010).
118. Herbst, R. S. et al. A first-in-human study of conatumumab in adult patients with advanced solid tumors. Clin. Cancer Res. 16, 5883-5891 (2010).
119. Doi, T. et al. Phase 1 study of conatumumab, a pro-apoptotic death receptor 5 agonist antibody, in Japanese patients with advanced solid tumors. Cancer Chemother. Pharmacol. 68, 733-741 (2010).
120. Wakelee, H. A. et al. Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors. Ann. Oncol. 21, 376-381 (2010).
121. Pardee, A. D., Wesa, A. K. & Storkus, W. J. Integrating costimulatory agonists to optimize immune-based cancer therapies. Immunotherapy 1, 249-264 (2009).
122. Moore, P. A. et al. BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science 285, 260-263 (1999).
123. O'Connor, B. P. et al. BCMA is essential for the survival of long-lived bone marrow plasma cells. J. Exp. Med. 199, 91-98 (2004).
124. Benson, M. J. et al. Cutting edge: the dependence of plasma cells and independence of memory B cells on BAFF and APRIL. J. Immunol. 180, 3655-3659 (2008).
125. Mackay, F & Schneider, P. Cracking the BAFF code. Nature Rev. Immunol. 9, 491-502 (2009).
126. Grewal, I. S. & Flavell, R. A. CD40 and CD154 in cell-mediated immunity. Annu. Rev. Immunol. 16, 111-135 (1998).
127. Vonderheide, R. H. et al. Clinical activity and immune modulation in cancer patients treated with CP-870, 893, a novel CD40 agonist monoclonal antibody. J. Clin. Oncol. 25, 876-883 (2007).
128. Advani, R. et al. Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma. J. Clin. Oncol. 27, 4371-4377 (2009).
129. Beatty, G. L. et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 331, 1612-1616 (2011).
130. Kwon, B. S. & Weissman, S. M. cDNA sequences of two inducible T-cell genes. Proc. Natl Acad. Sci. USA 86, 1963-1967 (1989).
131. Vinay, D. S. & Kwon, B. S. 4-1BB signaling beyond T cells. Cell. Mol. Immunol. 8, 281-284 (2011).
132. Cannons, J. L. et al. 4-1BB ligand induces cell division, sustains survival, and enhances effector function of CD4 and CD8 T cells with similar efficacy. J. Immunol 167, 1313-1324 (2001).
133. Zhu, Y, Zhu, G., Luo, L, Flies, A. S. & Chen, L. CD137 stimulation delivers an antigen-independent growth signal for T lymphocytes with memory phenotype. Blood 109, 4882-4889 (2007).
134. + cytolytic T cells and responsiveness to IL-2 but not cytolytic activity. J. Immunol. 169, 4230-4236 (2002).
135. Wilcox, R. A. et al. Cutting edge: expression of functional CD137 receptor by dendritic cells. J. Immunol. 168, 4262-4267 (2002).
136. Melero, I. et al. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nature Med. 3, 682-685 (1997).
137. Narazaki, H., Zhu, Y., Luo, L., Zhu, G. & Chen, L. CD137 agonist antibody prevents cancer recurrence: contribution of CD137 on both hematopoietic and nonhematopoietic cells. Blood 115, 1941-1948 (2010).
138. Zhang, N. et al. Targeted and untargeted CD137L fusion proteins for the immunotherapy of experimental solid tumors. Clin. Cancer Res. 13, 2758-2767 (2007).
139. + T cells and inhibit tumor growth in mice. J. Clin. Invest. 118, 376-386 (2008).
140. Murillo, O. et al. In vivo depletion of DC impairs the anti-tumor effect of agonistic anti-CD137 mAb. Eur. J. Immunol. 39, 2424-2436 (2009).
141. Palazon, A. et al. Agonist anti-CD137 mAb act on tumor endothelial cells to enhance recruitment of activated T lymphocytes. Cancer Res. 71, 801-811 (2011).
142. + cytolytic T lymphocytes in vivo. Blood 103, 177-184 (2004).
143. Sun, Y et al. Administration of agonistic anti-4-1BB monoclonal antibody leads to the amelioration of experimental autoimmune encephalomyelitis. J. Immunol. 168, 1457-1465 (2002).
144. + T cells. Blood 105, 2206-2213 (2005).
145. Foell, J. L. et al. Engagement of the CD137 (4-1BB) costimulatory molecule inhibits and reverses the autoimmune process in collagen-induced arthritis and establishes lasting disease resistance. Immunology 113, 89-98 (2004).
146. Lee, J. et al. Administration of agonistic anti-4-1BB monoclonal antibody leads to the amelioration of inflammatory bowel disease. Immunol. Lett. 101, 210-216 (2005).
147. Sun, Y. et al. Inhibition of Th2-mediated allergic airway inflammatory disease by CD137 costimulation. J. Immunol. 177, 814-821 (2006).
148. + subsets via CD137 in type 1 diabetes. Diabetes 56, 186-196 (2007).
149. Sun, Y. et al. Costimulatory molecule-targeted antibody therapy of a spontaneous autoimmune disease. Nature Med. 8, 1405-1413 (2002).
150. 1 mice. J. Clin. Invest. 111, 1505-1518 (2003).
151. Wang, J. et al. CD137-mediated pathogenesis from chronic hepatitis to hepatocellular carcinoma in hepatitis B virus-transgenic mice. J. Immunol. 185, 7654-7662 (2010).
152. Lee, S. W., Salek-Ardakani, S., Mittler, R. S. & Croft, M. Hypercostimulation through 4-1BB distorts homeostasis of immune cells. J. Immunol. 182, 6753-6762 (2009).
153. Zhu, G. et al. Progressive depletion of peripheral B lymphocytes in 4-1BB (CD137) ligand/I-Eα-transgenic mice. J. Immunol. 167, 2671-2676 (2001).
154. Ascierto, P. A., Simeone, E., Sznol, M., Fu, Y. X. & Melero, I. Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies. Semin. Oncol. 37, 508-516 (2010).
155. Piconese, S., Valzasina, B. & Colombo, M. P. OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection. J. Exp. Med. 205, 825-839 (2008).
156. Hirschhorn-Cymerman, D. et al. OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis. J. Exp. Med. 206, 1103-1116 (2009).
157. Hendriks, J., Xiao, Y. & Borst, J. CD27 promotes survival of activated T cells and complements CD28 in generation and establishment of the effector T cell pool. J. Exp. Med. 198, 1369-1380 (2003).
158. Sakanishi, T. & Yagita, H. Anti-tumor effects of depleting and non-depleting anti-CD27 monoclonal antibodies in immune-competent mice. Biochem. Biophys. Res. Commun. 393, 829-835 (2010).
159. Song, D. G. et al. CD27 costimulation augments the survival and anti-tumor activity of redirected human T cells in vivo. Blood 119, 696-706 (2011).
160. Ramirez-Montagut, T. et al. Glucocorticoid-induced TNF receptor family related gene activation overcomes tolerance/ignorance to melanoma differentiation antigens and enhances antitumor immunity. J. Immunol. 176, 6434-6442 (2006).
161. + effector T cells in mediating agonistic anti-GITR mAb-induced-immune activation and tumor immunity in CT26 tumors. J. Immunol. 179, 7365-7375 (2007).
162. + regulatory T cells through GITR breaks immunological self-tolerance. Nature Immunol. 3, 135-142 (2002).
163. + regulatory T cells. J. Immunol. 171, 708-716 (2003).
164. + T cells. J. Immunol. 173, 5008-5020 (2004).
165. Bollag, G. et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 467, 596-599 (2010).
166. Kohrt, H. E. et al. Effect of stimulation of natural killer cells with an anti-CD137 mAb on the efficacy of trastuzumab, cetuximab, and rituximab. J. Clin. Oncol. Abstr. 30, 2514 (2012).
167. Azimzadeh, A. M., Lees, J. R., Ding, Y. & Bromberg, J. S. Immunobiology of transplantation: impact on targets for large and small molecules. Clin. Pharmacol. Ther. 90, 229-242 (2011).
168. Arkin, M. R. & Wells, J. A. Small-molecule inhibitors of protein-protein interactions: progressing towards the dream. Nature Rev. Drug Discov. 3, 301-317 (2004).
169. Emerson, S. D. et al. NMR characterization of interleukin-2 in complexes with the IL-2Rα receptor component, and with low molecular weight compounds that inhibit the IL-2/IL-Rα interaction. Protein Sci. 12, 811-822 (2003).
170. Erbe, D. V., Wang, S., Xing, Y. & Tobin, J. F. Small molecule ligands define a binding site on the immune regulatory protein B7.1. J. Biol. Chem. 277, 7363-7368 (2002).
171. Margolles-Clark, E., Umland, O., Kenyon, N. S., Ricordi, C. & Buchwald, P. Small-molecule costimulatory blockade: organic dye inhibitors of the CD40-CD154 interaction. J. Mol. Med. 87, 1133-1143 (2009).
172. Lipson, E. J. et al. Durable cancer regression off-treatment and effective re-induction therapy with an anti-PD-1 antibody. Clin. Cancer Res. 20 Nov 2012 (doi:10.1158/1078-0432.CCR-12-2625).
173. Younes, A. et al. A Phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphoma. Br. J. Cancer 103, 1783-1787 (2010).